JP2024520132A - 向知性薬としてのｌｉｎｅ－１阻害剤 - Google Patents

向知性薬としてのｌｉｎｅ－１阻害剤 Download PDF

Info

Publication number
JP2024520132A
JP2024520132A JP2023574354A JP2023574354A JP2024520132A JP 2024520132 A JP2024520132 A JP 2024520132A JP 2023574354 A JP2023574354 A JP 2023574354A JP 2023574354 A JP2023574354 A JP 2023574354A JP 2024520132 A JP2024520132 A JP 2024520132A
Authority
JP
Japan
Prior art keywords
line
inhibitor
subject
disorder
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520132A5 (enExample
Inventor
エッカルト ウェーバー
アンドリュー サトリン
Original Assignee
トランスポゾン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスポゾン セラピューティクス インコーポレイテッド filed Critical トランスポゾン セラピューティクス インコーポレイテッド
Publication of JP2024520132A publication Critical patent/JP2024520132A/ja
Publication of JP2024520132A5 publication Critical patent/JP2024520132A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023574354A 2021-06-04 2022-06-03 向知性薬としてのｌｉｎｅ－１阻害剤 Pending JP2024520132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197015P 2021-06-04 2021-06-04
US63/197,015 2021-06-04
PCT/US2022/032120 WO2022256625A1 (en) 2021-06-04 2022-06-03 Line-1 inhibitors as cognitive enhancers

Publications (2)

Publication Number Publication Date
JP2024520132A true JP2024520132A (ja) 2024-05-21
JP2024520132A5 JP2024520132A5 (enExample) 2024-08-05

Family

ID=84323626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574354A Pending JP2024520132A (ja) 2021-06-04 2022-06-03 向知性薬としてのｌｉｎｅ－１阻害剤

Country Status (10)

Country Link
US (1) US20240285664A1 (enExample)
EP (1) EP4346835A4 (enExample)
JP (1) JP2024520132A (enExample)
KR (1) KR20240017910A (enExample)
CN (1) CN117813096A (enExample)
AU (1) AU2022283915A1 (enExample)
CA (1) CA3221190A1 (enExample)
IL (1) IL309036A (enExample)
MX (1) MX2023014381A (enExample)
WO (1) WO2022256625A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4358968A4 (en) * 2021-06-22 2025-05-07 Rome Therapeutics, Inc. 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES
EP4482498A4 (en) * 2022-02-22 2026-02-25 Rome Therapeutics Inc METHODS OF TREATING MEDICAL PROBLEMS USING CENSAVUDINE OR A COMBINATION COMPOUND
US20250186475A1 (en) * 2022-03-15 2025-06-12 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
WO2024107850A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066677A2 (en) * 2001-02-20 2002-08-29 European Molecular Biology Laboratory Model of transmissible spongiform encephalopathic (tse) disease
WO2020154656A1 (en) * 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2020185676A1 (en) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986891C (en) * 2015-05-26 2022-01-04 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
IL301564A (en) * 2020-09-23 2023-05-01 Transposon Therapeutics Inc LINE-1 inhibitors to treat the disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066677A2 (en) * 2001-02-20 2002-08-29 European Molecular Biology Laboratory Model of transmissible spongiform encephalopathic (tse) disease
WO2020154656A1 (en) * 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2020185676A1 (en) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"オンコリスバイオファーマ株式会社 (4588 Mothers） −OBP-601の新規機序の潜在力−", ANALYST NET COMPANY REPORT, JPN6026021514, 8 July 2020 (2020-07-08), ISSN: 0005871789 *
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 5, JPN6026021515, 2001, pages 1539 - 1546, ISSN: 0005871790 *
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 15, JPN6026021516, 2004, pages 169 - 187, ISSN: 0005871791 *
プリオン病診療ガイドライン ２０２０, JPN6026021517, 23 March 2020 (2020-03-23), ISSN: 0005871792 *

Also Published As

Publication number Publication date
KR20240017910A (ko) 2024-02-08
EP4346835A4 (en) 2025-04-16
US20240285664A1 (en) 2024-08-29
MX2023014381A (es) 2023-12-15
AU2022283915A1 (en) 2024-01-18
CA3221190A1 (en) 2022-12-08
WO2022256625A1 (en) 2022-12-08
IL309036A (en) 2024-02-01
CN117813096A (zh) 2024-04-02
EP4346835A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7136886B2 (ja) Ｈｉｖカプシド阻害剤の固体形態
US11826363B2 (en) Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
AU2015371255B2 (en) Fused pyrimidine compounds for the treatment of HIV
KR20240017910A (ko) 인지 향상제로서 line-1 억제제
US10112922B2 (en) Inhibitor of bruton's tyrosine kinase
JP4629104B2 (ja) ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
JP2021510163A (ja) ベンズアミド化合物
JP2024511973A (ja) Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤
AU2020286339B2 (en) Compositions and methods for inhibiting kinases
CA3183081A1 (en) Combination therapy for treatment of cancer
UA129653C2 (uk) Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування
EP0777669B1 (en) 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent
US20160287553A1 (en) Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
DK2555775T3 (en) Combination Compositions of Adenosine A1 Agonists and Carbonic Anhydrase Inhibitors to Reduce Intraocular Pressure
CN108348524A (zh) 用于从中风恢复的方法和组合物
JP2002534390A (ja) 癌治療におけるアデノシンアゴニスト類の使用
CA3124714A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
TW201736391A (zh) 作為人類鼻病毒抑制劑之炔基核苷類似物
TW202116301A (zh) 藥物組合及其用途
US11717511B2 (en) Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer
CA3119395C (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
RU2825271C2 (ru) Макроциклические соединения в качестве агонистов sting и способы с их использованием и пути их применения
CA3119395A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2010083645A1 (en) PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
WO2009110416A1 (ja) 併用剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260528

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260625

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260728